• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-甲基地高辛在人体内的处置

Disposition of beta-methyldigoxin in man.

作者信息

Rietbrock N, Abshagen U, Bergmann K, Rennekamp H

出版信息

Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):105-14. doi: 10.1007/BF00614005.

DOI:10.1007/BF00614005
PMID:1233258
Abstract

The time course of radioactivity in plasma and the excretion in urine and faeces over 7 days were determined in 12 healthy subjects after single oral and intravenous doses of a solution of 3H-beta-methyldigoxin. 62.2 +/- 2.1 and 29.0 +/- 5.2 per cent of the dose were excreted in urine and faeces, respectively, within 7 days of intravenous administration, compared with 55.2 +/- 2.8 and 28.6 +/- 5.7 per cent after oral administration. This indicates almost complete absorption of the glycoside when given in solution. 12 hours after its administration a pseudo-distribution equilibrium was reached and the average half life of tritiated compounds was 1.3 days. By 48 - 96 hours after treatment the average half life was 2.8 days. O-demethylation was revealed as the main metabolic degradation step in man. The rate of Demethylation was higher after oral than i.v. administration. Thus, only 31% of the radioactivity excreted in the urine consisted of unchanged beta-methyl-digoxin after oral administration compared to 51% after i.v. dosing. Only traces of bis- and monoglycosides were excreted in urine, but there were considerable amounts in faeces, where they accounted for more than 35% of the total excretion. Up to 40% of the radioactivity in plasma and urine consisted of polar conjugates during the first 12 hours after administration of beta-methyldigoxin. The mono- and bisglycosides were identified as the main products of conjugation. During the 7 days approximately 15% of the administered dose was metabolized by splitting off glycosidic bonds and conjugation to polar compounds.

摘要

在12名健康受试者单次口服和静脉注射3H-β-甲基地高辛溶液后,测定了7天内血浆中放射性的时程以及尿液和粪便中的排泄情况。静脉给药后7天内,分别有62.2±2.1%和29.0±5.2%的剂量经尿液和粪便排泄,口服给药后则分别为55.2±2.8%和28.6±5.7%。这表明该糖苷以溶液形式给药时几乎完全吸收。给药12小时后达到假分布平衡,氚标记化合物的平均半衰期为1.3天。治疗后48 - 96小时,平均半衰期为2.8天。O-去甲基化被证明是人体主要的代谢降解步骤。口服给药后的去甲基化速率高于静脉给药。因此,口服给药后经尿液排泄的放射性中只有31%为未变化的β-甲基地高辛,而静脉给药后这一比例为51%。尿液中仅排泄出痕量的双糖苷和单糖苷,但粪便中有相当数量,它们占总排泄量的35%以上。在给予β-甲基地高辛后的最初12小时内,血浆和尿液中高达40%的放射性由极性缀合物组成。单糖苷和双糖苷被鉴定为缀合的主要产物。在7天内,约15%的给药剂量通过糖苷键断裂和与极性化合物缀合而代谢。

相似文献

1
Disposition of beta-methyldigoxin in man.β-甲基地高辛在人体内的处置
Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):105-14. doi: 10.1007/BF00614005.
2
Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.
J Pharm Sci. 1977 Mar;66(3):314-25. doi: 10.1002/jps.2600660304.
3
Pharmacokinetics of beta-methyldigoxin in healthy humans I: intravenous studies.健康人体中β-甲基地高辛的药代动力学I:静脉注射研究
J Pharm Sci. 1977 Feb;66(2):242-53. doi: 10.1002/jps.2600660228.
4
Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.螺内酯预处理对人4'''-甲基地高辛药代动力学的影响。
Naunyn Schmiedebergs Arch Pharmacol. 1976;292(1):87-92. doi: 10.1007/BF00506494.
5
Tissue distribution and elimination of digoxin and methyldigoxin after single and multiple doses in dogs.犬单次及多次给药后地高辛和甲地高辛的组织分布与消除
J Cardiovasc Pharmacol. 1979 Mar-Apr;1(2):219-34. doi: 10.1097/00005344-197903000-00005.
6
Bioavailability and pharmacokinetics of beta-methyldigoxin after multiple oral and intravenous doses.多次口服和静脉给药后β-甲基地高辛的生物利用度和药代动力学
Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):373-9. doi: 10.1007/BF00606551.
7
[Pharmacokinetic studies on fluoro-alpha-acetyl-digoxin (author's transl)].
Arzneimittelforschung. 1978;28(2):322-5.
8
[Pharmacokinetics of digoxin and methyldigoxin in patients with acute hepatitis (author's transl)].急性肝炎患者地高辛和甲基地高辛的药代动力学(作者译)
Med Klin. 1978 Mar 31;73(13):463-9.
9
Absorption of beta-methyl-digoxin determined after a single dose and under steady state conditions.单次给药后及稳态条件下测定的β-甲基地高辛的吸收情况。
Eur J Clin Pharmacol. 1976 Feb 6;9(4):307-14. doi: 10.1007/BF00561665.
10
Metabolism of labetalol by animals and man.拉贝洛尔在动物和人体内的代谢。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):695-710.

引用本文的文献

1
Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides.强心苷的比较药代动力学和药效学
Br J Clin Pharmacol. 1980 Aug;10(2):135-43. doi: 10.1111/j.1365-2125.1980.tb01730.x.
2
Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.药物及其他外来化合物的药理活性代谢产物。临床、药理、治疗及毒理学考量。
Drugs. 1982 Dec;24(6):519-42. doi: 10.2165/00003495-198224060-00003.
3
Bioavailability and pharmacokinetics of beta-methyldigoxin after multiple oral and intravenous doses.

本文引用的文献

1
Deposition and disappearance of digitoxin from the tissues of the rat, rabbit, and dog after parenteral injection.
Circulation. 1952 Sep;6(3):367-70. doi: 10.1161/01.cir.6.3.367.
2
The tissue distribution and excretion of radioactive digitoxin; studies on normal rats and cats, and rats with dietary induced myocardial lesions.放射性洋地黄毒苷的组织分布与排泄;对正常大鼠和猫以及饮食诱导心肌损伤大鼠的研究
Circulation. 1952 Apr;5(4):496-503. doi: 10.1161/01.cir.5.4.496.
3
The deposition of digitoxin in the tissues of the rat after parenteral injection.
Circulation. 1951 Jul;4(1):105-7. doi: 10.1161/01.cir.4.1.105.
4
多次口服和静脉给药后β-甲基地高辛的生物利用度和药代动力学
Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):373-9. doi: 10.1007/BF00606551.
4
Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.药理活性药物代谢物:治疗及毒性活性、人体血浆及尿液数据、肾衰竭时的蓄积情况
Clin Pharmacokinet. 1976 Nov-Dec;1(6):426-43. doi: 10.2165/00003088-197601060-00003.
[CONJUGATION OF CARDENOLIDE GENINS WITH SULFURIC ACID OR GLUCURONIC ACID].
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1964 Jun 22;248:370-86.
5
[Distribution, excretion and metabolism of digitoxin in rats].[地高辛在大鼠体内的分布、排泄及代谢]
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1958;233(3):271-83.
6
[Behavior of cardiac glycosides in human organism. A review based on the example of digoxin and lanatoside C].
Ther Umsch. 1971 Apr;28(4):205-11.
7
[Comulative behavior of various cardiac glycosides in anuria].
Dtsch Med Wochenschr. 1970 Feb 27;95(9):444-50 passim. doi: 10.1055/s-0028-1108482.
8
[Metabolism and kinetics of -acetyldigoxin].[乙酰地高辛的代谢与动力学]
Klin Wochenschr. 1972 Feb 15;50(4):191-5. doi: 10.1007/BF01487142.
9
The clinical pharmacology of digitalis glycosides: a review.洋地黄苷类的临床药理学:综述
Am J Med Sci. 1968 Jun;255:382-414. doi: 10.1097/00000441-196806000-00006.
10
Pharmacokinetics and metabolism of digoxigenin-mono-digitoxoside in man.洋地黄毒苷元-单洋地黄毒糖苷在人体内的药代动力学与代谢
Eur J Clin Pharmacol. 1974;7(2):87-94. doi: 10.1007/BF00561320.